Comorbid functional pathology in gastroenterology. Possibilities and prospects for drug treatment: A review

• Published in: Consilium medicum (Online) Vol. 25; no. 12; pp. 844 - 848
• Main Authors: Osadchuk, Alexey M., Loranskaya, Irina D., Osadchuk, Mikhail A.
• Format: Journal Article
• Language: English; Russian
• Published: ZAO "Consilium Medicum" 12-03-2024
• Subjects: crossover of functional disorders of the gastrointestinal tract; functional diseases of the gastrointestinal tract; new effects of trimebutine; prebiotics; probiotics; trimebutine
• ISSN: 2075-1753; 2542-2170
• DOI: 10.26442/20751753.2023.12.202529

Functional disorders of the gastrointestinal tract (FD GT) and their intersection are relevant due to their high prevalence in the population, decrease and, in some cases, loss of performance, low quality of life and treatment difficulties. Despite the large number of consensuses and clinical recommendations at the national and international level, the effectiveness of therapy for FD GT and their overlap does not exceed 30-50%. There is a high degree of comorbidity of these diseases, called “overlap syndromes,” due to common pathogenetic mechanisms. This predetermines the need to use drugs with a multi-target therapeutic effect in the treatment of such pathology. Such drugs include trimebutine (Trimedate®), probiotics and psychotropic drugs. Data obtained in recent years on the presence of anti-inflammatory, antimicrobial, regenerative effects in relation to nervous and epithelial tissue and anti-carcinogenic effects in trimebutine make it unique for the treatment of gastrointestinal diseases and their intersection. Currently, there is a search for new promising drugs for the treatment of both individual FD GT and their overlap, as well as improving the regimens of existing treatment methods. The review article is devoted to existing opportunities and new horizons for the treatment of FD GT and their overlap.